PerkinElmer

In June, the FDA cleared tests for a broad range of conditions, including Group B strep, systemic rheumatic disease, and chlamydial or gonococcal urogenital disease.

The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.

The immunofluorescence assays support the detection of anti-double-stranded DNA, which is a marker for systemic lupus erythematosus.

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

The company said revenues in its diagnostics business unit rose 62 percent during the quarter.

The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.

The company plans to use the proceeds to repay loan and revolving credit facilities incurred to pay a portion of its 2017 acquisition of Euroimmun.

The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.

Pages